Altitudes Sickness

Altitude sickness refers to a spectrum of non-traumatic medical conditions that occur due to the reduced partial pressure of oxygen at high altitudes (hypobaric hypoxia). It primarily affects individuals who ascend too quickly to altitudes generally above 2,500 meters (8,000 feet) without adequate acclimatization. The conditions range from the mild and common Acute Mountain Sickness (AMS) to the life-threatening High-Altitude Pulmonary Edema (HAPE) and High-Altitude Cerebral Edema (HACE). Timely recognition and descent are crucial for preventing severe outcomes.

The primary cause of altitude sickness is hypobaric hypoxia, a reduction in the partial pressure of oxygen (PO2) in the ambient air as atmospheric pressure decreases with increasing altitude. This leads to a decreased PO2 in the alveoli and arterial blood, impairing oxygen delivery to tissues. Individual susceptibility, genetics, rate of ascent, altitude attained, and duration of exposure are key determinants. Lifestyle factors such as exertion at altitude and inadequate hydration can exacerbate symptoms, but are not primary causes. Pre-existing medical conditions like chronic lung disease or heart failure can increase risk.

At higher altitudes, reduced atmospheric pressure directly lowers the partial pressure of inspired oxygen (PiO2). This leads to a decrease in alveolar oxygen (PAO2) and arterial oxygen (PaO2), triggering a hypoxic ventilatory response (hyperventilation) to increase PAO2 and PaO

1. However, if ascent is too rapid, the body cannot adequately acclimatize.

Altitude sickness is common, affecting millions of travelers annually. The incidence varies significantly with altitude and rate of ascent. AMS occurs in approximately 25-80% of individuals ascending to 2,500-3,500 meters, and its prevalence increases dramatically above 3,500 meters. HAPE is less common, affecting 0.1-4% of individuals, depending on altitude and individual susceptibility. HACE is the rarest and most severe form, occurring in about 0.5-1% of individuals at extreme altitudes. Age, gender, and physical fitness do not consistently predict susceptibility, although individuals with a history of altitude sickness are at higher risk for recurrence.

• Rapid ascent to high altitude
• Previous history of altitude sickness
• Ascent to very high or extreme altitudes (>3,500 m)
• Exertion at altitude before acclimatization
• Residing at low altitude (<900 m) before ascent
• Untreated sleep apnea
• Pre-existing cardiovascular or pulmonary conditions (though individuals with severe conditions are advised against high-altitude travel)
• Certain genetic predispositions (under research)

A. Early Symptoms (typically 6-12 hours after ascent)

• Headache (often throbbing, worsened by exertion)


• Nausea and/or vomiting


• Fatigue or weakness


• Dizziness or lightheadedness


• Difficulty sleeping (insomnia, fragmented sleep) B. Common Symptoms (progression of early symptoms, or for moderate AMS)


• Loss of appetite


• Malaise


• Irritability


• Persistent headache


• Mild shortness of breath on exertion C. Advanced Symptoms (signs of HACE or HAPE)


• Severe headache unresponsive to analgesics


• Ataxia (loss of coordination, difficulty walking a straight line – cardinal sign of HACE)


• Confusion, disorientation, altered mental status


• Visual disturbances or hallucinations


• Severe shortness of breath at rest (HAPE)


• Persistent cough, sometimes producing pink, frothy sputum (HAPE)


• Chest tightness or congestion (HAPE)


• Decreased urine output D. Emergency Symptoms


• Loss of consciousness, coma


• Profound weakness, inability to walk


• Cyanosis (bluish discoloration of lips, nail beds)


• Severe respiratory distress, gasping for air


• Severe confusion or psychotic behavior


• Seizures

• Vital signs: Tachycardia, tachypnea, often normal temperature (or mild fever with HAPE), low oxygen saturation (SpO2) on pulse oximetry.
• Inspection: Signs of distress, cyanosis (late), ataxia (tandem gait test for HACE), altered mental status, peripheral edema.
• Palpation: No specific findings directly related to altitude sickness.

• Pulmonary: Clear lungs with AMS. Crackles/rales (often bilateral, sometimes asymmetric) with HAPE. Rhonchi may be present.

A. Clinical Assessment
Diagnosis is primarily clinical, based on recent ascent to altitude, presence of typical symptoms, and exclusion of other conditions. The Lake Louise Consensus Score is a widely used clinical tool for diagnosing AMS.
B. Laboratory Testing
Not typically required for initial diagnosis but can help exclude other conditions or assess severity.
C. Imaging Studies
Chest X-ray for HAPE, CT/MRI of the brain for HACE.
D. Functional Tests
Pulse oximetry to assess oxygen saturation.
E. Biopsy Findings
Not applicable.
F. Genetic Testing
Not routinely used in clinical practice, but research is ongoing into genetic predispositions.
G. Differential Diagnosis
Dehydration, exhaustion, viral illness, migraine, carbon monoxide poisoning, hypothermia, pneumonia, pulmonary embolism.

Pulse Oximetry
Type: Non-invasive measurement
Purpose: To assess arterial oxygen saturation (SpO2).
Expected Findings: SpO2 typically <90% at moderate altitude in symptomatic individuals; may be <80% in severe cases of HAPE/HACE.
Interpretation: Low SpO2 indicates hypoxemia, a hallmark of altitude sickness. Correlates with severity but is not diagnostic on its own. Arterial Blood Gas (ABG)
Type: Blood Test
Purpose: To provide a precise assessment of oxygenation (PaO2), carbon dioxide (PaCO2), and acid-base status.
Expected Findings: Hypoxemia (low PaO2), often with respiratory alkalosis (low PaCO2, elevated pH) due to hyperventilation, potentially compensated by metabolic acidosis (low bicarbonate).
Interpretation: Confirms the degree of hypoxia and helps evaluate the body's compensatory mechanisms, especially useful in severe cases.

Chest X-ray (CXR) for HAPE
Purpose: To detect and assess the extent of pulmonary edema.
Typical Findings: Bilateral patchy infiltrates (often perihilar or asymmetric), pulmonary vascular congestion, enlarged pulmonary arteries. Cardiomegaly is usually absent.
Clinical Importance: Confirms the diagnosis of HAPE, helps rule out other causes of dyspnea and cough, and guides treatment decisions. CT/MRI of Brain for HACE
Purpose: To detect cerebral edema and rule out other intracranial pathologies (e.g., hemorrhage, stroke).
Typical Findings: Diffuse white matter edema, sulcal effacement, ventricular compression, increased signal on T2-weighted MRI sequences.
Clinical Importance: Confirms the diagnosis of HACE, assesses the severity of cerebral edema, and guides emergency management.

• Dehydration: Shares symptoms like headache and fatigue, but vital signs and lack of altitude-specific symptoms help distinguish.
• Exhaustion: Similar fatigue, but resolves with rest and lacks other AMS features.
• Migraine: Can cause severe headache and nausea, but typically has a pre-existing history and may include aura; usually no altitude correlation.
• Viral Illness (e.g., common cold, influenza): Can mimic AMS symptoms; fever and specific respiratory symptoms might indicate viral illness, but difficult to distinguish early.
• Carbon Monoxide Poisoning: Can cause headache, nausea, dizziness. Requires CO monitoring for diagnosis; often linked to faulty heating/cooking at altitude.
• Hypothermia: Confusion, lethargy, and ataxia can overlap; distinguished by low core body temperature.
• Pneumonia/Bronchitis: Cough, fever, and dyspnea can mimic HAPE; specific lung findings on exam and imaging, and often higher fever with pneumonia.
• Pulmonary Embolism: Sudden dyspnea, chest pain; less common but critical to consider.

• Death: Untreated HACE or HAPE can be rapidly fatal.
• Cerebral Herniation: Due to severe brain swelling in HACE.
• Permanent Neurological Deficits: Rare but possible after severe HACE (e.g., cognitive impairment, motor deficits).
• Acute Respiratory Failure: From severe pulmonary edema in HAPE.
• Pulmonary Hypertension: Rarely, repeated severe HAPE episodes may contribute to chronic pulmonary hypertension, but this is not a common complication for most individuals.

A. Lifestyle Modifications

• Acclimatization: Gradual ascent (no more than 300-600 m/day above 2,500 m, with rest days every 2-3 days).


• Hydration: Drink plenty of fluids.


• Avoid overexertion: Limit strenuous activity upon arrival at altitude.


• Avoid alcohol and sedatives: Especially in the first 24-48 hours, as they can depress respiratory drive. B. Preventive Measures


• Gradual Ascent: The most effective prevention. "Climb high, sleep low" strategy.

• Dexamethasone: Alternative for those intolerant to acetazolamide, or for rapid ascent where acetazolamide is insufficient. C. Medical Treatment


• Descent: The definitive treatment for all forms of altitude sickness. Even a few hundred meters can provide relief.


• Supplemental Oxygen: Administer oxygen to maintain SpO2 >90%.

• Moderate to Severe: Descent, oxygen, Acetazolamide (250 mg BID), Dexamethasone (4 mg Q6h) for severe symptoms or if descent is not immediately possible.

• Oxygen therapy.


• Nifedipine (extended release 30 mg BID or 10 mg sublingual then 30 mg ER BID): reduces pulmonary artery pressure.


• Tadalafil (10 mg BID) or Sildenafil (50 mg TID): phosphodiesterase-5 inhibitors, also reduce pulmonary artery pressure.

• Oxygen therapy.


• Dexamethasone (8 mg loading dose, then 4 mg Q6h): reduces cerebral edema.


• Portable hyperbaric bags (e.g., Gamow bag) can simulate descent if actual descent is delayed. D. Surgical Treatment

The prognosis for altitude sickness is generally excellent with early recognition and appropriate management, especially prompt descent. Most individuals with AMS recover fully within 24-48 hours after descent or acclimatization. HAPE and HACE are potentially fatal if untreated, but rapid descent and medical intervention usually lead to full recovery. Untreated HACE can result in permanent neurological damage or death. Repeated episodes of HAPE, especially in susceptible individuals, might rarely contribute to long-term pulmonary vascular changes.

Primary Prevention: Gradual Ascent: Ascend slowly, allowing time for acclimatization. Above 2,500m, limit ascent to 300-600m per day, with a rest day every 2-3 days.

• "Climb High, Sleep Low": During an ascent, it's beneficial to hike to a higher altitude during the day and return to a lower altitude to sleep.


• Hydration: Maintain adequate fluid intake.


• Avoid Alcohol and Sedatives: Especially during the initial days at altitude.


• Prophylactic Medications: Acetazolamide (24 hours before ascent) or Dexamethasone (for those intolerant to acetazolamide or for rapid ascent).

• Immediate Action: Stop ascending, rest, and consider descent at the first sign of symptoms. Treat with oxygen and medications as appropriate.

The following homeopathic remedies have been historically indicated for symptoms associated with Altitudes Sickness. Selection should be based on individualized symptom totality and constitutional assessment.

• Homeopathy by Hadhrat Mirza Tahir Ahmad (r.a.) — Primary clinical reference
• Robin Murphy — Lotus Materia Medica (3rd Edition)
• William Boericke — Pocket Manual of Homœopathic Materia Medica & Repertory
• ICD-10/ICD-11 Classification — World Health Organization
• Harrison's Principles of Internal Medicine (Reference Standard)

This clinical reference profile is compiled from authoritative medical sources for educational purposes. Always verify clinical data with current medical guidelines.

📊 Epworth Sleepiness Scale (ESS)

Evaluates daytime sleepiness levels to screen for sleep apnea, narcolepsy, or chronic sleep deprivation disorders.